Shanghai Lishan Biotech is a biotech company dedicated to AI-driven development of Live Biotherapeutic Products (LBPs) to address unmet clinical needs in inflammation, oncology, and neurological disorders.

Leveraging an "AI + microbiome" strategy, Lishan Biotech modulates the microbial ecosystem and intervenes in host pathways to generate synergistic effects, systematically pushing the boundaries of microbiome therapeutics in pursuit of First-in-Class and Best-in-Class innovations.

Employing the globally proprietary Swarming strain colonization technology and the pioneering Intelligent Microbiome Application Platform (IMicAP), Lishan Biotech is accelerating its growth into a globally leading innovative platform enterprise in the microbiome therapeutics space, establishing itself as an indispensable core enabling hub.